Belite Bio Announces Availability of Annual Report on Form 20-F

Belite Bio, Inc. announced on March 31, 2026, that its annual report on Form 20-F for the year ended December 31, 2025, has been filed with the Securities and Exchange Commission and is available on the company's website. Shareholders can request a hard copy free of charge. The press release is issued in accordance with Nasdaq Listing Rule 5250(d)(1)(C). Belite Bio is a clinical-stage company developing therapeutics for degenerative retinal diseases like Stargardt disease and geographic atrophy, as well as metabolic diseases. Their lead candidate, tinlarebant, is an oral therapy targeting bisretinoid toxin accumulation in the eye. The company has completed a Phase 3 trial for STGD1 and is conducting further trials for STGD1 and GA.